The €37m CoreMap round shows where med-tech VCs are actually putting money right now
The quietest €37 million raised in Irish med-tech this year belongs to a company most people outside cardiology circles have never heard of. CoreMap, a precision cardiac mapping business, closed a Series C round that would barely register against the noise of consumer AI fundraises. That is exactly why it matters.
The condition nobody talks about until it talks about them
Atrial fibrillation is the most common cardiac arrhythmia in the world. The European Heart Journal puts the European patient count at around 14 million, and that figure is projected to more than double by 2060 as populations age. In Ireland alone, the Irish Heart Foundation estimates roughly 70,000 people are living with AF right now, a number that grows by thousands each year.
The problem is not that we lack treatment. Catheter ablation, the procedure that isolates or destroys the rogue electrical pathways causing AF, has been around for decades. The problem is precision. Ablation success rates hover somewhere between 60 and 80 percent for a first procedure, depending on the complexity of the case. Failed procedures mean repeat interventions, longer hospital stays, and escalating costs that the HSE and every other European health system can barely absorb. CoreMap is attacking that failure rate directly, using detailed electroanatomical mapping to tell the electrophysiologist exactly where to burn and where not to.
That is not a nice-to-have feature. That is a cost-reduction argument wrapped in a clinical outcome. It is the kind of pitch that gets a Series C done.
Why this round tells you something about where med-tech capital is going
Consumer AI gets the front pages. Precision healthcare gets the term sheets. The pattern across European med-tech funding in 2024 and into 2025 is consistent: capital is concentrating in companies that sit at the intersection of diagnostics, data, and high-volume chronic disease management. AF ticks every box.
Three reasons explain why cardiac tech specifically is attracting this level of investor attention right now.
1. The reimbursement pathway is already built. The single biggest risk for a med-tech investor is not whether the technology works. It is whether a health system will pay for it. AF ablation is an established, reimbursed procedure across Europe and the US. CoreMap is not asking payors to create a new category. It is improving a workflow they already fund. That de-risks the commercial path considerably.
2. The addressable market is enormous and growing without any marketing effort. Demographic ageing is not a trend that requires a customer acquisition budget. The patients are coming regardless. A company that improves outcomes in a condition tied directly to an ageing population has a structural tailwind that no amount of economic turbulence will reverse.
3. The data moat builds with every procedure. Every ablation guided by CoreMap's system generates proprietary procedural data. More data refines the mapping algorithms. Better algorithms improve outcomes. Better outcomes drive adoption. That is a compounding asset, not a one-time product sale, and it is the kind of business model that justifies a Series C valuation.
What the €37 million actually means in real terms
Thirty-seven million euro sounds like an abstraction until you translate it. At a cost of roughly €15,000 to €25,000 per AF ablation procedure in a European private hospital setting, that round represents the equivalent revenue of somewhere between 1,500 and 2,500 completed procedures. It is not cash to be spent on brand awareness campaigns or standing desks in a new Dublin office. Series C capital at this level funds clinical trial expansion, regulatory submissions across new markets, and the commercial infrastructure to get into catheterisation labs in Germany, France, and the US.
The order of deployment matters here.
Step 1: Regulatory clearance. Without CE mark expansion or FDA clearance in the target markets, the product cannot be sold. This comes first, full stop.
Step 2: Clinical validation at scale. Cardiologists do not switch procedural tools on the basis of a brochure. They switch on the basis of published outcomes data from institutions they respect. This step is expensive, slow, and non-negotiable.
Step 3: Commercial team build. Only after steps one and two are credible do you spend on a sales organisation. Building a sales team before you have regulatory clearance and clinical evidence is how med-tech companies burn through a Series C and arrive at Series D in a weak position.
Step 4: Payor engagement. Getting a technology embedded in clinical guidelines and reimbursement frameworks is a multi-year process. You start it early, but you win it late.
The Irish angle that investors are missing
Ireland has an outsized med-tech heritage relative to its size. The west of Ireland corridor from Galway to Limerick houses manufacturing or R&D operations for Boston Scientific, Medtronic, Abbott, and a dozen others. That cluster did not happen by accident. It reflects decades of engineering talent development, IDA investment, and proximity to European regulatory frameworks.
What Irish investors have been slower to do is back the indigenous companies that should logically emerge from that ecosystem. Irish med-tech startups are already missing opportunities in adjacent device categories, and the CoreMap raise should prompt a serious conversation about whether domestic VC appetite is keeping pace with the quality of founders coming out of that cluster.
The fear is understandable. Med-tech has longer development cycles than software, heavier regulatory burdens, and capital requirements that dwarf a typical SaaS seed round. The opportunity is that those same barriers keep the competition thin and the margins fat once you clear them.
The close
Investors who are waiting for med-tech to become as legible and fast-moving as software are going to keep waiting. The CoreMap round is not a story about speed. It is a story about building something that a health system cannot afford to ignore because the alternative is worse outcomes and higher costs. That is a business worth backing, even if it never trends on LinkedIn.
Cheap is not a strategy in cardiac care. Precision is.
